Desmoid Tumor | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Desmoid tumours (DT), also known as deep fibromatosis or desmoid-type fibromatosis, are rare monoclonal tumors that originate from spindle-shaped mesenchymal fibroblast-like cells. According to estimates, DT occurs in 2-4 people per million, accounting for 0.03% of all neoplasms. The peak age for incidents is between 30 and 40. Women have a higher likelihood of developing it than men do between the ages of 15 and 60. Desmoid tumors (DT) can develop intra-abdominally. Primary surgery with negative surgical margins is the most successful first line treatment for desmoid tumors. Positive surgical margins are a sign that there is a high risk of recurrence. Nonsteroidal anti-inflammatory drugs, hormonal therapy, and cytotoxic chemotherapy are occasionally used in addition to surgery, with the latter being the most effective pharmacological approach.

Description

Desmoid tumours (DT), also known as deep fibromatosis or desmoid-type fibromatosis, are rare monoclonal tumors that originate from spindle-shaped mesenchymal fibroblast-like cells. DTs can be distinguished from superficial fibromatoses such as Dupuytren disease and penile and palmar fibromatosis (Peyronie disease) by their location, molecular causes, and clinical traits. DTs exhibit strong infiltrative expansion and frequently recur locally. Desmoid tumors can impair functioning, cause serious treatment-related morbidity, and even cause death while remaining benign because they cannot metastasize.

Desmoid Tumor (Epidemiology)

According to estimates, 2-4 cases of DT occur per million people, accounting for 0.03% of all neoplasms. The peak age for incidents is between 30 and 40 years old. Women are more likely than men between the ages of 15 and 60 to develop it. DT can occur inside the abdominal cavity, outside it, or anywhere in the abdominal area. Familial adenomatous polyposis (FAP) is responsible for 5 to 10% of cases.

Desmoid Tumor -Current Market Size & Forecast Trends

The global market for desmoid tumors is expected to grow significantly, with a projected value of approximately USD 5.2 billion by 2033, up from around USD 2.5 billion in 2023, representing a compound annual growth rate (CAGR) of 7.6% during the forecast period from 2024 to 2033. This growth is driven by factors such as increasing awareness of desmoid tumors, advancements in diagnostic imaging, and the development of targeted therapies. The market is characterized by a strong focus on surgical interventions and the use of medical therapies to manage tumor growth. North America is anticipated to dominate the market, accounting for a significant share due to its advanced healthcare infrastructure and ongoing research initiatives, while the Asia-Pacific region is expected to exhibit the fastest growth rate, fueled by rising patient populations and improved access to treatment options. As research progresses and new therapies are introduced, the desmoid tumor market is poised for continued expansion through 2035.

Primary surgery with favorable surgical margins is the most effective initial treatment for desmoid tumors. Positive surgical margins are a sign that there is a high risk of recurrence. Nonsteroidal anti-inflammatory drugs, hormonal therapy, and cytotoxic chemotherapy are occasionally used in addition to surgery; the latter is the most effective pharmacological approach. Since desmoid tumors do not spread, many treatments are nonoperative in nature. Desmoid tumors may stabilize and regress, making active observation a possibility. Radiation therapy can be used as a primary treatment for recurrent disease or as a preventive measure to avoid mutilating surgical resection. It may be used as the sole mode of treatment, postoperatively, or even in the operating room. Drug therapy may also involve the use of prostaglandin inhibitors and antiestrogens. Pharmacologic treatments have objective response rates between 40 and 50%, though response times can vary. When surgery is not an option or in situations where there has been a recurrence, chemotherapy using doxorubicin, dacarbazine, and carboplatin may be helpful. Intra-abdominal desmoid tumors connected to Gardner syndrome may respond to systemic doxorubicin, and patients with tumor-related complications may benefit from ifosfamide. Targeted therapy based on imatinib and polychemotherapy may be used in conjunction. Increased knowledge of the molecular underpinnings of familial adenomatosis polyposis-desmoid tumor may aid in the development of novel therapeutic strategies. Magnetic resonance-guided high-intensity focused ultrasound may prove to be a safe and effective treatment option for some desmoid tumors.

Report Highlights

Desmoid Tumor - Current Market Trends

Desmoid Tumor - Current & Forecasted Cases across the G8 Countries

Desmoid Tumor - Market Opportunities and Sales Potential for Agents

Desmoid Tumor - Patient-based Market Forecast to 2035

Desmoid Tumor - Untapped Business Opportunities

Desmoid Tumor - Product Positioning Vis-a-vis Competitors' Products

Desmoid Tumor - KOLs Insight